Three stories to remind you of the power (Back to Top) of prevention

F.D.A. grants new approvals for immunotherapies to treat metastatic CRC

On July 18, 2017, the U.S. Food and Drug Administration approved three new treatments for colorectal cancer, allowing patients to continue the fight against one of the most common and deadly forms of the disease. The new drugs, approved as monotherapies, are part of a larger effort to improve outcomes for patients with metastatic colorectal cancer (mCRC). The new drugs include Nivolumab (Opdivo), Pembrolizumab (Keytruda), and Ipilimumab (Yervoy).

In this Newsletter:

Three stories to remind you of the power (Back to Top) of prevention

FDA grants new approvals for immunotherapies to treat metastatic CRC

The costs of CRC drugs continue to climb

U.S. colorectal cancer drugs market size, by drug class

F.D.A. grants new approvals for immunotherapies to treat metastatic CRC

On July 18, 2017, the U.S. F.D.A. approved the use of pembrolizumab (also known as Keytruda) in combination with docetaxel chemotherapy for the treatment of patients with advanced or metastatic colorectal cancer, who have not previously received any prior treatment. Pembrolizumab is a monoclonal antibody that targets the PD-1 receptor on immune cells, which helps the immune system detect and destroy cancer cells. Pembrolizumab is being studied in combination with several other drugs, including chemotherapy, radiation therapy, and targeted drugs, for the treatment of various types of cancer, including colorectal cancer.

The costs of CRC drugs continue to climb

U.S. colorectal cancer drugs market size, by drug class

On July 18, 2017, the F.D.A. approved the use of irinotecan (also known as CPT-11) for the treatment of patients with advanced or metastatic colorectal cancer, who have not previously received any prior treatment. Irinotecan is a topoisomerase I inhibitor that works by preventing the formation of DNA strands, which stops cancer cells from dividing and growing. Irinotecan is being studied in combination with several other drugs, including chemotherapy, radiation therapy, and targeted drugs, for the treatment of various types of cancer, including colorectal cancer.

U.S. colorectal cancer drugs market size, by drug class

On July 18, 2017, the F.D.A. approved the use of trastuzumab (also known as Herceptin) for the treatment of patients with advanced or metastatic colorectal cancer, who have not previously received any prior treatment. Trastuzumab is a monoclonal antibody that targets the HER2 receptor on cancer cells, which helps the immune system detect and destroy cancer cells. Trastuzumab is being studied in combination with several other drugs, including chemotherapy, radiation therapy, and targeted drugs, for the treatment of various types of cancer, including colorectal cancer.

For more information on these and other colorectal cancer drugs, visit the American Cancer Society’s website at cancer.org.

In conclusion:

Three stories to remind you of the power (Back to Top) of prevention

F.D.A. grants new approvals for immunotherapies to treat metastatic CRC

The costs of CRC drugs continue to climb

U.S. colorectal cancer drugs market size, by drug class

In conclusion:

Three stories to remind you of the power (Back to Top) of prevention

F.D.A. grants new approvals for immunotherapies to treat metastatic CRC

The costs of CRC drugs continue to climb

U.S. colorectal cancer drugs market size, by drug class

Three stories to remind you of the power (Back to Top) of prevention

F.D.A. grants new approvals for immunotherapies to treat metastatic CRC

The costs of CRC drugs continue to climb

U.S. colorectal cancer drugs market size, by drug class

In conclusion:

Three stories to remind you of the power (Back to Top) of prevention

F.D.A. grants new approvals for immunotherapies to treat metastatic CRC

The costs of CRC drugs continue to climb

U.S. colorectal cancer drugs market size, by drug class

In conclusion:

Three stories to remind you of the power (Back to Top) of prevention

F.D.A. grants new approvals for immunotherapies to treat metastatic CRC

The costs of CRC drugs continue to climb

U.S. colorectal cancer drugs market size, by drug class

In conclusion:

Three stories to remind you of the power (Back to Top) of prevention

F.D.A. grants new approvals for immunotherapies to treat metastatic CRC

The costs of CRC drugs continue to climb

U.S. colorectal cancer drugs market size, by drug class

In conclusion:

Three stories to remind you of the power (Back to Top) of prevention

F.D.A. grants new approvals for immunotherapies to treat metastatic CRC

The costs of CRC drugs continue to climb

U.S. colorectal cancer drugs market size, by drug class

In conclusion:

Three stories to remind you of the power (Back to Top) of prevention

F.D.A. grants new approvals for immunotherapies to treat metastatic CRC

The costs of CRC drugs continue to climb

U.S. colorectal cancer drugs market size, by drug class

In conclusion:

Three stories to remind you of the power (Back to Top) of prevention

F.D.A. grants new approvals for immunotherapies to treat metastatic CRC

The costs of CRC drugs continue to climb

U.S. colorectal cancer drugs market size, by drug class

In conclusion:

Three stories to remind you of the power (Back to Top) of prevention

F.D.A. grants new approvals for immunotherapies to treat metastatic CRC

The costs of CRC drugs continue to climb

U.S. colorectal cancer drugs market size, by drug class

In conclusion:

Three stories to remind you of the power (Back to Top) of prevention

F.D.A. grants new approvals for immunotherapies to treat metastatic CRC

The costs of CRC drugs continue to climb

U.S. colorectal cancer drugs market size, by drug class

In conclusion:

Three stories to remind you of the power (Back to Top) of prevention

F.D.A. grants new approvals for immunotherapies to treat metastatic CRC

The costs of CRC drugs continue to climb

U.S. colorectal cancer drugs market size, by drug class

In conclusion:

Three stories to remind you of the power (Back to Top) of prevention

F.D.A. grants new approvals for immunotherapies to treat metastatic CRC

The costs of CRC drugs continue to climb

U.S. colorectal cancer drugs market size, by drug class